Back to today’s briefing

Story perspectives

Pfizer Stock Soars 5.2% After Strong Q2 Earnings

8/5/2025

46 9

Summary

Story summary

Pfizer's stock increased by 5.2% after surpassing Q2 earnings expectations with 78 cents per share on $14.65 billion in sales.
The company aims to reduce costs by $7.7 billion by 2027 to tackle R&D challenges.
Covid product sales thrived, with Comirnaty and Paxlovid earning $381 million and $427 million, respectively.
Pfizer adjusted its annual sales forecast to $61-$64 billion and earnings outlook to $2.90-$3.10 per share.

1 of 1

Story summary

Pfizer's stock increased by 5.2% after surpassing Q2 earnings expectations with 78 cents per share on $14.65 billion in sales.
The company aims to reduce costs by $7.7 billion by 2027 to tackle R&D challenges.
Covid product sales thrived, with Comirnaty and Paxlovid earning $381 million and $427 million, respectively.
Pfizer adjusted its annual sales forecast to $61-$64 billion and earnings outlook to $2.90-$3.10 per share.